Please ensure Javascript is enabled for purposes of website accessibility

Why Sarepta Pharmaceuticals, Tech Data, and Cliffs Natural Resources Jumped Today

By Dan Caplinger – Sep 19, 2016 at 4:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These stocks helped keep the overall market from falling. Find out why.

Image source: Cliffs Natural Resources

The stock market got off to a good start on Monday, although the day's gains evaporated throughout the trading session to leave major market benchmarks unchanged by the market close. For the most part, investors have appeared reluctant to make predictions about the results of this week's meeting of the U.S. central bank's Federal Open Market Committee, which will decide whether or not to continue raising short-term interest rates. Until recently, a Fed hike seemed to be off the table, and even though market participants are bracing for a potential increase, today suggested that the arguments favoring a wait-and-see attitude could be gaining ground. In addition, many stocks posted significant increases, including Sarepta Therapeutics (SRPT -2.42%), Tech Data (TECD), and Cliffs Natural Resources (CLF -5.89%).

Sarepta finally gets its FDA approval

Sarepta Therapeutics soared almost 75% after the U.S. Food and Drug Administration gave final accelerated approval for the company's Duchenne Muscular Dystrophy drug eteplirsen. Sarepta shares had been extremely volatile in recent weeks, as the departure of a former panel member at the FDA raised hopes that the drug might end up getting fast-tracked through the approval process. Going forward, Sarepta expects to market eteplirsen under the name Exondys 51, which refers to the specific part of the genetic code that the drug aims to skip in order to try to restore normal function. Sarepta said that the approval is contingent on confirmation in clinical trials, but investors are happy to have the final decision in place.

Tech Data makes a big buy

Tech Data jumped 22% on news that it will buy the technology solutions business of Avnet (AVT -1.95%) for $2.6 billion. Under the terms of the deal, Tech Data will pay $2.4 billion in cash and also give Avnet 2.785 million shares of its stock. Tech Data CEO Bob Dutkowsky characterized the deal as "transformative," arguing that the move will "create a premier global IT distributor with the most diverse end-to-end solutions from the data center to the living room." Going forward, Tech Data hopes that the deal will help the company capitalize more fully on next-generation technological advances, especially those related to the cloud computing movement. Avnet shares also gained ground, but their 7% rise made it clear that Tech Data shareholders think their company is getting the better end of the deal.

Cliffs holds its own

Finally, Cliffs Natural Resources picked up 6%. The producer of iron ore has seen tough times over the past several years as the market for steel production has fallen prey to a lull in global construction activity. Low steel prices produce less demand for iron ore as a raw material, but more recently, calls for another wave downward in the steel market haven't proven out. With the iron ore market seeming to be more resilient than expected, investors in Cliffs Natural Resources hope that the company will finally get some help from the broader market and find a way to accelerate its profit growth going forward.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool owns shares of Cliffs Natural Resources. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cliffs Natural Resources Inc. Stock Quote
Cliffs Natural Resources Inc.
$13.27 (-5.89%) $0.83
Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$108.19 (-2.42%) $-2.68
Avnet, Inc. Stock Quote
Avnet, Inc.
$36.29 (-1.95%) $0.72
Tech Data Corporation Stock Quote
Tech Data Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.